All posts by imreal

Orthopedic & Sports Physical Therapy Expands Footprint through Partnership with Versailles Physical Therapy and Hand Clinic


News Image

“OSPT has been a foundational partner of the Confluent Health family and we are excited to welcome Versailles PT. Bringing in Versailles PT will add significant value as we grow together. Our partnership has endless possibilities.” – Larry Benz, Confluent Health’s President and CEO

Orthopedic & Sports Physical Therapy (OSPT) is proud to announce its partnership with Versailles Physical Therapy and Hand Clinic (Versailles PT), a therapist-owned physical therapy practice located in Versailles, Kentucky. The partnership is an exciting opportunity for both companies to expand their reach and provide even more comprehensive care to patients throughout the region.

“We have been searching for a reputable business partner that can help us continue along this growth trajectory, and it’s for this reason that we couldn’t be more excited to partner with OSPT,” said Beth Coon, DPT, CHT, CEO of Versailles PT. “Their established practice has a sterling reputation for compassionate patient care and top-notch customer service. We can’t wait to see what this partnership will bring!”

Versailles PT patients will continue to receive the same high-quality care from the same familiar faces they know and trust. However, the clinical team will now have access to OSPT’s parent company, Confluent Health, and their established ecosystem of management services as well as education and musculoskeletal health resources. Support services include efficient community outreach, digital innovations, value-based care pathway models, and marketing and finance tools. Resources include best

in brand physical therapy partnerships, such as the PTPN network, continuing education programs and staff development opportunities with Evidence in Motion, a nationally recognized residency, fellowship, and certification education provider in physical and occupational therapy programs and Fit For Work, the leading provider of employee safety.

“Since opening our doors, our vision has been to provide the highest level of service to our patients and referring physicians throughout all of our clinics and across the state of Kentucky and Indiana,” said Bradley Wheeldon, PT, MPT, Co-founder of OSPT.

“We are delighted that this partnership will allow us to continue this vision and reach more residents than before.”

This partnership will further expand OSPT’s footprint, making it the proud owner of nine clinics across Kentucky and Indiana. “This partnership will empower us to reach more patients in Kentucky, expand our services and provide an even higher level of comprehensive care. Together, we are poised to make a positive impact on the lives of individuals throughout the region,” said Jim Rothbauer, PT, MPT, ATC, Co-Founder of OSPT.

Confluent Health’s President and CEO, Larry Benz, PT, DPT, OCS, MBA, MAPP, states, “OSPT has been a foundational partner of the Confluent Health family and we are excited to welcome Versailles PT. Bradley’s team is made up of pre-eminent clinical leaders, and bringing in Versailles PT is going to add significant value as we grow together. Our partnership has endless possibilities.”

For more information about OSPT, visit their website at osptky.com. To schedule an appointment with one of Versailles PT’s expert therapists, visit their website at versaillesphysicaltherapy.com or call 859- 879-3560.

###

About Orthopedic & Sports Physical Therapy: Orthopedic & Sports Physical Therapy (OSPT) is a Kentucky-based, private physical therapy practice group. As a proud member of the Confluent Health family, OSPT positively impacts patients’ lives by delivering the best care and results through proven research, innovative treatments and technologies, and an approach that treats patients like family. For more information, visit osptky.com, or find them on Facebook at @osptky.

About Confluent Health: Confluent Health is a family of physical and occupational therapy companies. We are transforming healthcare by strengthening private practices, developing highly effective clinicians, innovating new services and technology to improve the quality of care for patients, and lowering costs via

more effective treatment, workplace wellness, and injury prevention. For more information, visit goconfluent.com or find us on Facebook at @confluenthealth.

Share article on social media or email:

Proem to Showcase Behavioral Health Assessment Tools at DIA 2023


See Proem Behavioral Health at Booth 1144 during the DIA 2023 Global Annual Meeting in Boston.

“We look forward to showing attendees of DIA 2023 why clinical researchers are increasingly using Proem’s exclusively licensed digital assessments,” said Proem CEO John Letter.

Proem Behavioral Health, which offers one of the most used and validated sets of behavioral health assessment tools available, invites attendees of the DIA 2023 Global Annual Meeting in Boston from June 25–29 to visit Proem at Booth 1144.

The Proem solution helps clinical researchers more accurately and consistently screen for and diagnose the most common DSM-5 mental health disorders to assist with trial participant selection and ongoing monitoring. Using Proem, researchers are empowered to select the right trial participants to keep studies on track and get neuropsychiatric drugs, therapies and devices to market more quickly, safely and cost-effectively.

Proem is the exclusive worldwide digital licensee of clinically validated scales written by world-renowned psychiatrists and used by researchers for more than 25 years in more than 100 countries. Proem licensed digital scales include the Mini International Neuropsychiatric Interview (M.I.N.I.), M.I.N.I. KID, Sheehan Disability Scale (SDS), Sheehan-Suicidality Tracking Scale (S-STS), Yale-Brown Obsessive Compulsive Scale (YBOCS I&II), Childrens Yale-Brown Obsessive Compulsive Scale (CYBOCS I&II), Body Dysmorphic Disorder Questionnaire (BDDQ), and more.

Proem’s exclusively licensed scales have been cited in more than 175,000 articles and used in worldwide studies reviewed by the U.S. Food and Drug Administration (FDA), National Institutes of Health (NIH), National Institutes of Mental Health (NIMH), World Health Organization (WHO), European Pharmaceutical Associations, and Federation of Asian Pharmaceutical Associations.

Key benefits of the Proem solution include the following

  • Speed of screening — Significantly decrease the time it takes to administer mental health assessments for potential trial participants.
  • Accurate data — Accurate screening and assessment results better ensure the right candidates are included in studies and trials.
  • Remove bias — Using digital tools eliminates manual patient screening processes that can introduce screener bias.
  • Decrease scoring errors — Digital solutions also drastically cut scoring errors associated with manual tools.
  • Native language — Reliable translation services preserve the integrity of the tools in any language.

“At Proem, we are committed to partnering with clinical researchers to help them effectively identify and recruit the trial participants they need and accomplish their study objectives,” said Proem CEO John Letter. “We look forward to showing attendees of DIA 2023 why clinical researchers are increasingly using our digital assessments and why we believe ‘healthy minds start with Proem.'”

ABOUT PROEM BEHAVIORAL HEALTH

Proem Behavioral Health provides the premier clinical workflow software engine that helps behavioral health providers, substance use disorder clinics and research organizations efficiently and accurately screen, test and measure treatment success for those suffering from mental illness. Proem is the exclusive digital licensee worldwide of gold-standard, evidence-based screening solutions, structured interviews and post-diagnosis severity measurement scales to monitor patient outcomes. To learn more, visit proemhealth.com and follow Proem on LinkedIn and Twitter.

Share article on social media or email:



Ideal Option Opens Addiction Medicine Clinic in Van Buren


Ideal Option, a national leader in evidence-based outpatient treatment for addiction to fentanyl, heroin, methamphetamine, alcohol and polysubstance, is now welcoming new patients in Van Buren. The new clinic, located at 2521 Alma Hwy, provides primarily buprenorphine-based medication-assisted treatment. While opioid prescribing and heroin use is on the decline, overdose deaths continue to increase in Arkansas, largely due to the prevalence of fentanyl in the illicit drug supply. According to the Arkansas Take Back Opioid Dashboard, overdose deaths in Crawford County increased by over 250% from 2019 to 2020 and remained consistent from 2020 to 2021. In addition, narcotic arrests increased by 13% from 2020 to 2021. Fentanyl is regularly mixed with other illicit drugs to make them more addictive, often without the user knowing. Polysubstance use disorder is therefore now the most common diagnosis at Ideal Option. According to their 2022 Annual Patient Outcomes Report showing aggregated lab testing results for more than 1,000 patients in Arkansas, over 50% of patients tested positive for more than one substance at enrollment, and 24% tested positive for three or more substances. The report does offer hope, however, by showing how effective medication-assisted treatment is for reducing isolated and polysubstance use. For patients who remained in treatment with Ideal Option during 2022, lab testing shows:


  • 87% less total opioid use
  • 94% less fentanyl use
  • 96% less heroin use
  • 77% less methamphetamine use
  • 90% less cocaine use

The new clinic in Van Buren is Ideal Option’s eleventh location in Arkansas and is opening at a time of desperate need for expanded access to evidence-based treatment from experienced providers. Ideal Option has been specializing in addiction medicine using buprenorphine-based medications such as Suboxone® for 11 years and currently operates 91 clinics in 11 states. “We continue to see a rapid rise in fentanyl use across Arkansas, creating an urgent need for specialized treatment, which is limited in Crawford County,” said Aaron Bunch, community outreach coordinator for Ideal Option. “Ideal Option provides a low-barrier, safe, judgment-free space for individuals to receive this life-saving treatment. I am excited to get the word out in Van Buren and look forward to building relationships within the community.” The new outpatient clinic in Van Buren is open Monday – Thursday, 7:30 a.m. – 6 p.m., at 2521 Alma Hwy. Ideal Option also has a clinic in Fort Smith, located at 1100 Lexington Ave. Most forms of insurance are accepted, including Medicare and Medicaid, and patients can typically get started on treatment for fentanyl, heroin, alcohol or other substances within 1-3 business days. Patients can make an appointment by calling 1.877.522.1275 or visiting http://www.idealoption.com.

About Ideal Option

Headquartered in Kennewick, Washington, Ideal Option was founded in 2012 and has since helped more than 70,000 patients through a network of 91 office-based medication-assisted treatment (MAT) clinics across 11 states. With a mission to serve under-served communities, Ideal Option accepts most forms of insurance including Medicaid and Medicare. Financial assistance and payment plans are also available. Ideal Option’s team of medical providers carry certifications in Addiction and Emergency Medicine, Internal, and Family Medicine, among other specialties. The company also employs social workers, caseworkers, counselors, and mental health practitioners. This holistic approach helps drive positive outcomes, including family stability, stable housing, improved overall health, and reduced rates of recidivism. In all the communities it serves, Ideal Option collaborates with existing stakeholders and providers to improve the continuum of care. This approach includes partnerships with emergency rooms and county jail systems, where individuals with substance use disorder often appear, as well as collaborating with numerous support agencies and municipal programs addressing social needs such as housing, mental health, and nutrition support.

Share article on social media or email:

Ideal Option Releases Patient Outcomes Report to Show Effectiveness of Medication-Assisted Treatment for Fentanyl and Methamphetamine Use


Ideal Option, a national leader in outpatient medication-assisted treatment for addiction to opioids and other substances, has released its 2022 Annual Patient Outcomes Report.

This report contains an aggregated view of patients’ geographic and demographic characteristics, their stage and duration of care, adherence to medication and their substance use over time based on lab specimens collected during 2022 from nearly 15,000 patients.

The data support the effectiveness of treating addiction with FDA-approved medications combined with regular lab testing to verify medication adherence, create accountability and ensure patient safety.

Among patients who remained in treatment from initiation to the maintenance stage of care during 2022, the report shows:

  • 93% less total opioid use
  • 97% less fentanyl use
  • 95% less heroin use
  • 86% less methamphetamine use
  • 87% less cocaine use

The report also reveals synthetic drug use continuing to rise among enrolling patients in 2022, particularly fentanyl. Fentanyl is regularly mixed with other illicit drugs to make them more addictive, often without the user knowing.

“Polysubstance use disorder is now the most common diagnosis at Ideal Option,” said Tim Kilgallon, CEO at Ideal Option. “In 2022, over half of all patients tested positive for two or more substances at enrollment, and 27% tested positive for three or more substances.”

The data corroborate state reports of the increasingly prevalent role that fentanyl plays in the substance use epidemic, including Nebraska. According to Steven Bell, assistant special agent in charge of the DEA’s Omaha Division, around 1.5 million potentially lethal doses of fentanyl were distributed last year in Nebraska. In addition, Douglas County Attorney Don Kleine stated that known fentanyl overdose deaths in Douglas County increased by over 300% from nine in 2019 to 40 in 2021.

“Fentanyl and methamphetamine are the top two drug threats facing Nebraskans,” said DEA Omaha Division Special Agent in Charge Justin C. King in a recent statement. Ideal Option data show that standard treatment for opioid use disorder dramatically reduces the use of methamphetamine in patients who test positive for both.

View the full Ideal Option 2022 Annual Patient Outcomes Report here: [https://www.idealoption.com/patient-outcomes.

Ideal Option has helped more than 70,000 patients through a network of over 90 outpatient clinics across 11 states and opened in Omaha in December of last year.

With no waitlists and most forms of insurance accepted, including Medicare and Medicaid, patients can typically get started on treatment for fentanyl, heroin, methamphetamine, alcohol, or other substances within 1-3 business days.

The Ideal Option clinic in Omaha is open Monday – Thursday, 7:30 a.m. – 6 p.m. and is located at 13906 Gold Circle, Ste. 100.

Patients can make an appointment by calling 1.877.522.1275 or visiting http://www.idealoption.com.  

About Ideal Option 

Headquartered in Kennewick, Washington, Ideal Option was founded in 2012 and has since helped more than 70,000 patients through a network of over 90 office-based medication-assisted treatment (MAT) clinics across 11 states. With a mission to serve under-served communities, Ideal Option accepts all forms of insurance including Medicaid and Medicare. Financial assistance and payment plans are also available. 

Ideal Option’s team of medical providers carry certifications in Addiction and Emergency Medicine, Internal, and Family Medicine, among other specialties. The company also employs social workers, caseworkers, counselors, and mental health practitioners. This holistic approach helps drive positive outcomes, including family stability, stable housing, improved overall health, and reduced rates of recidivism. 

In all the communities it serves, Ideal Option collaborates with existing stakeholders and providers to improve the continuum of care. This approach includes partnerships with emergency rooms and county jail systems, where individuals with substance use disorder often appear, as well as collaborating with numerous support agencies and municipal programs addressing social needs such as housing, mental health, and nutrition support.

Share article on social media or email:

Author Introduces the Second Edition of His Guide to Supporting and Optimizing the Brain Naturally


David Tomen searched for years to find relief after his diagnosis of adult ADD and PTSD. After Ritalin lost its effectiveness, he began to read clinical studies to learn more about how Ritalin worked, searching for something new that would provide similar benefits. This led him to implement a methodically researched regimen of supplements and lifestyle changes, resulting in his brain working better than ever before.

Tomen is now sharing his story and research with others who are looking for ways to deal with their own brain health and cognition issues. In “Head First: 2nd Edition,” the author provides detailed reviews of 102 of the most popular natural supplements used today, supported by hundreds of peer-reviewed clinical studies from leading research institutions and universities around the world. Written in easy-to-understand language, readers can now decide which supplements they should try, and which ones they should avoid.

“There is no other book out there like ‘Head First,’” Tomen said. “The book is devoted exclusively to natural supplements, not smart drugs such as Ritalin or Adderall. You do not need a prescription for supplements because they can be found at any local health food store or vitamin shop.”

Tomen breaks down complex neuroscience and how the brain works, so readers can better understand how supplements work. He also includes two chapters on his recommendations that can be used to help those suffering from anxiety, autism, ADHD, depression, OCD, PTSD, traumatic brain injury and more.

“You can literally turn your life around if you take care of your Head First!” Tomen said. “This saved my life and I know that with this information you can get relief from whatever brain health issue you are dealing with too.”

“Head First: 2nd Edition”

By David Tomen

ISBN: 9798765236543 (softcover); 9798765236550 (hardcover); 9798765236581 (electronic)

Available at Balboa Press, Amazon and Barnes & Noble

About the author

For the last decade, author and world-traveler David Tomen has worked to deal with Adult ADD, as well as the brain fog, mental fatigue and memory loss that comes with hypothyroidism. Through studying clinical research and experimenting with dozens of supplements, Tomen has successfully restored his own health, finding that his cognition, memory, and mood were better than before. Through his writing and videos, Tomen wants to empower people to take control of their own cognitive health. To learn more, please visit his website.

General Inquiries:            

LAVIDGE – Phoenix                        

Ashley Fletcher

afletcher@lavidge.com

Share article on social media or email:

People who preserve ‘immune resilience’ live longer, resist infections


Immune resilience explains why some people, regardless of age, have impact immune systems and reduced inflammation. The blue-clad spheres are T-cells. The lower sphere is COVID-19.

Immune resilience is the capacity to maintain good immune function … and minimize inflammation while experiencing inflammatory stressors. —Weijing He, MD

Researchers from The University of Texas Health Science Center at San Antonio, working with collaborators in five countries, revealed that the capacity to resist or recover from infections and other sources of inflammatory stress — called “immune resilience” — differs widely among individuals. The researchers developed a unique set of metrics to quantify the level of immune resilience. This will aid in decisions for health care and help researchers understand differences in life span and health outcomes in persons of similar ages. These findings were published in Nature Communications.

The study was supported by a MERIT award and other grants from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health; awards from the U.S. Veterans Health Administration; and a Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation.

Not age-dependent

Although age plays an important role in the body’s response to infectious and other inflammatory stressors, some persons preserve and/or restore optimal immune resilience regardless of age, noted first and senior author Sunil K. Ahuja, MD, professor at UT Health Science Center San Antonio with a specialty in infectious diseases. He is director of the Veterans Administration (VA) Center for Personalized Medicine, a national center within the South Texas Veterans Health Care System.

“Immune resilience is the capacity to maintain good immune function, called immunocompetence, and minimize inflammation while experiencing inflammatory stressors,” said Weijing He, MD, co-author and senior research scientist at the VA Center for Personalized Medicine and Foundation for Advancing Veterans’ Health Research. “We found that during aging and when experiencing inflammatory stress, some persons resist degradation of immune resilience.”

Results

The laboratory tests developed to assess levels of immune resilience were evaluated in nearly 50,000 persons of differing ages and types of challenges to their immune systems. This evaluation demonstrated that individuals with optimal levels of immune resilience were more likely to:


  • Live longer.
  • Resist HIV and influenza infections.
  • Resist AIDS.
  • Resist recurrence of skin cancer after kidney transplant.
  • Survive COVID-19 infection.
  • Survive sepsis.

The researchers measured immune resilience in two ways:

  • By measuring the balance between CD8+ and CD4+ T-cells, which are types of white blood cells. T-cells fight infections, but an imbalance in their levels occurs in many infectious and autoimmune diseases. The balance between CD8+ and CD4+ T-cells, divided into four distinct categories called immune health grades, was measured in varied infection cohorts and across the age spectrum.
  • By measuring the expression levels of genes linked with immunocompetence and a greater chance of survival versus those linked with inflammation and a higher risk of death. The gene expression markers signifying high immunocompetence and low inflammation were identified with the immune health grade tracking optimal immune resilience.

“Many people think of inflammation alone when considering disease outcomes,” explained co-author Grace C. Lee, PharmD, PhD, research investigator at the VA Center for Personalized Medicine and assistant professor at The University of Texas at Austin College of Pharmacy. “However, the concept of immune resilience captures levels of immunocompetence and inflammation together.”

‘A step forward’

The study introduces the novel concept of immune resilience, which looks at the balance between immunocompetence and inflammation as a critical contributor to health outcomes, regardless of age. “This is an advantage and a step forward because by looking beyond inflammation, we may uncover new prevention and treatment strategies for chronic diseases such as cardiovascular disease, COVID-19, HIV/AIDS and cancers,” Lee said.

Framingham analysis

Muthu Saravanan Manoharan, MS, coauthor and senior research scientist at the VA Center for Personalized Medicine and UT Health Science Center San Antonio, noted that the study team divided participants from the Framingham Heart Study into four groups based on the gene expression markers of immune resilience. “Participants with optimal immune resilience, defined by gene expression markers signifying high immunocompetence and low inflammation, lived longer after controlling for the effects of age and sex,” Manoharan said. “Participants with metrics signifying low immunocompetence-high inflammation died sooner, whereas those with a combination of high immunocompetence-high inflammation, or low immunocompetence-low inflammation, had life spans that fell in between.”

Influenza

The study team also examined gene expression markers of immune resilience in a population of healthy college students and individuals in the community, all under age 50, who had blood drawn before the influenza season started. On the day of the first symptoms, most participants, including those with optimal immune resilience before the flu-like illness, had gene expression profiles indicating low immunocompetence and high inflammation, which is noted in persons with shorter life spans. Many people restored their initial level of immune resilience during recovery; however, even some of those who had optimal immune resilience before influenza infection failed to do so.

“Six months after their flu, some people continued to have gene expression signatures of poor immune health,” noted Nathan Harper, MS, coauthor and senior biostatistician at the VA Center for Personalized Medicine and Foundation for Advancing Veterans’ Health Research. “This is rather striking, because it means that inflammatory stressors like influenza can degrade a vulnerable person’s immune health long term.”

Sex workers

The study examined female sex workers from Kenya. During a long-term study, the immune health grades of those with unprotected sex decreased. “Most of the HIV acquisition occurred in women who had lower immune health grades,” said Lyle R. McKinnon, PhD, coauthor and associate professor in the Max Rady College of Medicine, Department of Medical Microbiology and Infectious Diseases, at the University of Manitoba, Canada. “With guidance and tools for safe sex practices, women with a lower frequency of unprotected sex over a 10-year time frame had restored optimal immune resilience, suggesting that removal of an immunological stressor could lead to the restoration of a healthier immune status.”

HIV-AIDS

In one of the cohorts, the authors observed a rare ability to maintain a high level of immunocompetence with a low level of inflammation despite chronic inflammatory stress, termed elite immune health status. “Interestingly, we found that some younger adults preserved optimal immune resilience markers despite HIV infection,” said Jason F. Okulicz, MD, U.S. Air Force infectious disease physician and senior member of the study team. “The preservation of these markers associated with resistance to developing AIDS and a low level of HIV in the blood. Remarkably, we found that after starting antiviral therapy early, some HIV-positive persons manifested markers of optimal immune resilience typically observed in younger adults without HIV infection.”

COVID-19

The association between immune resilience and the response to infection was noted during other infections. About 80% of individuals had poor immune health grades at presentation with acute COVID-19, and their immune grade predicted mortality, regardless of age. “Even among patients with serious community-acquired pneumonia and sepsis, those who had higher levels of gene expression markers of immune resilience at admission to the intensive care unit were more likely to survive,” noted coauthor Justin Meunier, BS, research scientist at the VA Center for Personalized Medicine.

Additional reading on this research:

Kidney transplant recipients

Immune resilience was also measured in kidney transplant recipients, who have a 100-fold excess risk of developing skin cancer. Each of the participants had developed this cancer once after transplant. “We explored the risk of getting a second cancer, dependent on immune health grades at the time each participant had the first cancer,” said Matthew J. Bottomley, MD, DPhil, academic clinical lecturer in the Nuffield Department of Surgical Sciences, University of Oxford. “We found that, if someone had optimal immune resilience at the time of the first cancer, they resisted getting their second cancer.”

In collaboration with investigators from Sardinia, the authors examined blood immune cell profiles of nearly 4,000 otherwise healthy individuals. “We found that irrespective of age, persons with poor immune resilience had immune cell profiles reflecting increased immune activation,” noted coauthor Edoardo Fiorillo, PhD, of the Institute for Genetic and Biomedical Research, National Council of Research, Lanusei, Italy. “Interestingly, we observed that nonhuman primates with poor immune resilience also manifested similar immune cell profiles.”

Females show greater immune resilience

One consistent finding throughout the populations studied was that age was not the single determinant factor in a person’s response to inflammatory stress. Some younger persons with poor immune resilience had the same signatures and immune health grades commonly seen in older persons. This finding suggests that the ability to restore and maintain immunocompetence at younger ages may be linked to life span. Another factor noted across the populations and species was that higher levels of optimal immune resilience were observed more often in females than males. Genetic studies in humans and evaluation of mice with a genetic basis to have lower immune resilience suggest that immune resilience may be calibrated by variations in genes. Notably, mice with lower immune resilience were most susceptible to severe Ebola infection.

Understanding risks

Public health ramifications of immune checkups could be significant, Ahuja said. He noted that assessment of immune health grades estimated by CD8+ and CD4+ counts is a simple way to monitor immune resilience. These assessments have utility for understanding who might be at greater risk for developing diseases that affect the immune system, how individuals are responding to treatment, and whether, as well as to what extent, they will recover.

Funding

This research was supported by the following funders: 1) National Institute of Allergy and Infectious Diseases (NIAID) through grant number R37AI046326 (MERIT award); 2) the U.S. Department of Veterans Affairs (VA) Center for Personalized Medicine through grant number IP1 CX000875-01A1 and a VA MERIT award; and 3) a Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation. The study with COVID-19 patients was supported by an inter-agency agreement (IAA) from the NIAID Division of Allergy, Immunology and Transplantation (DAIT) to the VA. DAIT manages this IAA; the IAA number is AAI21051-001-00000.

Immune resilience despite inflammatory stress promotes longevity and favorable health outcomes including resistance to infection

Sunil K. Ahuja, MD; Muthu Saravanan Manoharan, MS; Grace C. Lee, PharmD, PhD; Lyle R. McKinnon, PhD; Justin A. Meunier, BS; Maristella Steri, PhD; Nathan Harper, MS; Edoardo Fiorillo, PhD; Alisha M. Smith, PhD; Marcos I. Restrepo, MD, MSc, PhD; Anne P. Branum, BS; Matthew J. Bottomley, MD, DPhil; Valeria Orrù, PhD; Fabio Jimenez, BS; Andrew Carrillo, BS; Lavanya Pandranki, MS; Caitlyn A. Winter, MS; Lauryn A. Winter, MS; Alvaro A. Gaitan, MD; Alvaro G. Moreira, MD; Elizabeth A. Walter, MD; Guido Silvestri, MD; Christopher L. King, MD, PhD; Yong-Tang Zheng, PhD; Hong-Yi Zheng, PhD; Joshua Kimani, MD, MPH; T. Blake Ball, PhD; Francis A. Plummer, MD; Keith R. Fowke, PhD; Paul N. Harden, MD; Kathryn J. Wood, PhD; Martin T. Ferris, PhD; Jennifer M. Lund, PhD; Mark T. Heise, PhD; Nigel Garrett, MBBS, PhD; Kristen R. Canady, MD, PhD; Salim S. Abdool Karim, MD, PhD; Susan J. Little, MD; Sara Gianella, MD; Davey M. Smith, MD, MAS; Scott Letendre, MD; Douglas D. Richman, MD; Francesco Cucca, MD, PhD; Hanh Trinh, MD; Sandra Sanchez-Reilly, MD; Joan M. Hecht, RN; Jose Cadena, MD; Antonio Anzueto, MD; Jacqueline A. Pugh, MD; South Texas Veterans Health Care System COVID-19 team; Brian K. Agan, MD; Robert Root-Bernstein, PhD; Robert A. Clark, MD; Jason F. Okulicz, MD; Weijing He, MD

First published: Nature Communications, June 13, 2023

https://www.nature.com/articles/s41467-023-38238-6

The University of Texas Health Science Center at San Antonio (UT Health San Antonio), is one of the country’s leading health science universities and is designated as a Hispanic-Serving Institution by the U.S. Department of Education. With missions of teaching, research, patient care and community engagement, its schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have graduated more than 42,200 alumni who are leading change, advancing their fields and renewing hope for patients and their families throughout South Texas and the world. To learn about the many ways “We make lives better®,” visit UTHealthSA.org.

Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube.



Monster Energy’s Maycee Barber Defeats Amanda Ribas at UFC Fight Night Jacksonville


Monster Energy’s Maycee Barber Defeats Amanda Ribas And Earns the UFC’s $50,000 Performance of the Night Bonus at UFC Fight Night in Jacksonville, Florida

I feel like I’m a shark. I’m going to come for that blood, and when I see it, I’m coming for it!” – Maycee Barber

Another show-stopping victory! Monster Energy congratulates Maycee “The Future” Barber on defeating Amanda Ribas at UFC Fight Night Jacksonville. In the co-main event fight contested in the Women’s Flyweight division, the 25-year-old from Greeley, Colorado, brutalized her opponent to a second-round TKO victory. The no-holds-barred battle also earned Barber the UFC’s $50,000 Performance of the Night Bonus.

Also on the main card, 27-year-old Brendan Allen from Beaufort, South Carolina, dominated Brazil’s Bruno Silva to a spectacular submission victory in the first round.

UFC Fight Night: Emmett vs. Topuria was contested in front of a high-energy crowd inside VyStar Veterans Memorial Arena. With 14 fights on the card, the world-class fighting showcase was broadcast live on ESPN+ and ABC 5 Television.

Monster Energy’s Barber (13-2) came to Jacksonville riding a four-fight win streak after most recently defeating Andrea Lee at UFC Fight Night San Antonio in March 2023.

Her opponent, Brazilian MMA athlete Ribas (11-4), most recently earned a decision victory against Viviane Araujo at UFC 285 in March 2023. In terms of weight classes, Riba split time between strawweight and flyweight, and according to sports analysts, presented the biggest test of Barber’s career so far.

The pressure was palpable as the fight got underway, with Ribas edging Barber against the fence only to receive a fierce elbow to the face that opened a headwound early in the fight. Barber proved her strong takedown defense when Ribas attempted a headlock and answered a knee bar attempt by scoring big hits from the top. Gaining the upper hand, the end of Round 1 saw Barber dealing massive ground-and-pound damage as Ribas held on until the bell.

The second round started with Ribas returning fire after a takedown attempt and drawing blood from Barber. Showing her grit, Barber defended against headlock takedown and can opener attempts. Remaining on the offense, Barber continued to land significant shots while also sustaining visible damage in what proved one of the most ferocious and bloody fights the Women’s Flyweight division has seen to date.

Barber’s path to victory opened when she landed a stiff head kick that stunned Ribas, followed by a riveting right hand to the jaw. Seizing the moment, Barber swarmed her opponent with a heavy left-right combo that dropped Ribas to the canvas. Staying in close pursuit, Barber kept raining damaging elbows and punches on her bloodied adversary until referee Keith Peterson called a stop to the savage fight at 3:42 minutes, pronouncing Barber the winner by TKO.

“I feel like I’m a shark. I’m going to come for that blood, and when I see it, I’m coming for it!” said Barber upon winning her fight at UFC Fight Night Jacksonville, adding: “It feels like I just warned the whole 125-pound division that I’m back!”

Barber made her MMA debut on the Legacy Fighting Alliance (LFA) circuit. In 2018, she joined the Ultimate Fighting Championship (UFC) after a knockout performance on Dana White’s Contender Series and earned the nickname “The Future.”

New Monster Energy athlete “All In” Allen (22-5) came to Jacksonville on a four-fight win streak. Most recently, the rising middleweight contender defeated Andre Muniz in the headline fight at UFC Night 220 in February 2023. Previously, he defeated Krzysztof Jotko, Jacob Malkoun, and Sam Alvey and remains undefeated since February 2022.

Allen’s opponent, Silva (23-9) from Cajazeiras, Brazil, recently earned a thunderous first-round TKO victory over Brad Tavares at UFC Fight Night 222 in April. Would the Brazilian powerhouse put an end to Allen’s victory streak?

Opening the fight, Allen brought the pressure with several high kick attempts to keep Silva on his toes. After Silva defended against a takedown attempt, Allen landed a punishing elbow from the top. Silva stood his ground with a sharp punch that hurt Allen, only to collect instant payback by way of a clean punch followed by another takedown.

The fight’s decisive scene unfolded after Allen absorbed a heavy punch from Silva and fired back an unstoppable combo, dropping the Brazilian to the canvas with a clean right. With Silva slumped against the side of the cage, Allen assumed side control to lock in a rear-naked choke – and it was all over! At 4:39 minutes of Round 1, referee Marc Goddard declared Allen the winner by submission.

“I’m the youngest guy in the top 15 with some of the most fights. I’m really doing this, I’ve been out here, and I haven’t even reached my prime. I haven’t shown everything. I will be the next champion,” said Allen upon winning his fight at UFC Fight Night Jacksonville.

Looking ahead, Allen has his eyes on a title shot: “I’m the only guy to be able to threaten the actual champion everywhere. So, with that being said, Izzy… ‘And New’ in 2024! I’m coming!”

This win brings Allen’s professional record to 10 wins, two losses in the UFC promotion. Allen has now earned four of his past five wins via rear-naked choke submissions.

Allen made his professional MMA debut in 2015 and earned two Middleweight Championship titles in the Legacy Fighting Alliance promotion. After an outstanding performance on Dana White’s Contender Series in 2019, the black belt in Brazilian Jiu-Jitsu earned a UFC contract and has been climbing in the Middleweight division rankings.

Maycee Barber and Brendan Allen count amongst Monster Energy’s elite UFC athletes along with Kamaru Usman, Jon “Bones” Jones, Donald “Cowboy” Cerrone, Jorge “Gamebred” Masvidal, Chris “The All American” Weidman, Rose Namajunas, Tony Ferguson, Marlon Vera, Joanna Jędrzejczyk, Paulo “The Eraser” Costa, Stipe “Stone Cold” Miocic, Michael Chandler, Justin Gaethje, Jessica-Rose Clark, Valentina Shevchenko, Sean “Sugar” O’Malley, Brandon Moreno, Daniel Rodriguez, Alex Pereira, Punahele Soriano, Gilbert Burns, Giga “Ninja” Chikadze, Islam Makhachev, Johnny Walker, Beneil Dariush, and Gaston Bolanos.

For more on Monster Energy’s MMA athletes, visit http://www.monsterenergy.com. Follow Monster Energy on YouTube, Facebook, Instagram, Twitter and TikTok.

###

About Monster Energy

Based in Corona, California, Monster Energy is the leading marketer of energy drinks and alternative beverages. Refusing to acknowledge the traditional, Monster Energy supports the scene and sport. Whether motocross, off-road, NASCAR, MMA, BMX, surf, snowboard, ski, skateboard, or the rock and roll lifestyle, Monster Energy is a brand that believes in authenticity and the core of what its sports, athletes, and musicians represent. More than a drink, it’s the way of life lived by athletes, sports, bands, believers, and fans. See more about Monster Energy including all of its drinks at http://www.monsterenergy.com.



SandboxAQ Announces Bio-Pharma Molecular Simulation Division to Speed Life-Saving Drugs to Patients Through AI and Quantum Solutions


After several years of stealth development, SandboxAQ today formally announced its bio-pharma molecular simulation division, AQBioSim, and some of its customers and partners. The division is helping bio-pharma and research institutions achieve breakthroughs in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. The company is collaborating with a range of bio-pharma companies and university research labs, including AstraZeneca, Sanofi and UC San Francisco.

Paul Hudson, CEO of Sanofi said, “We are very interested in the work SandboxAQ is doing to revolutionize drug discovery and development via in-silico simulation of molecular interactions using AI and quantum technologies. SandboxAQ’s leapfrog technology could significantly impact both preclinical and clinical development of drugs, and we look forward to seeing how it could support us in delivering life-changing treatments to patients worldwide, faster.”

“SandboxAQ is at the forefront of combining AI and quantum techniques to address large, enterprise challenges. SandboxAQ’s technology is revolutionizing the drug discovery and development process,” said Eric Schmidt, Chairman of the Board of SandboxAQ.“ Through collaboration with Sanofi, UCSF and others, SandboxAQ is reducing the time and cost of bringing life-saving treatments to the clinic. This is just the beginning of the applications of AQ technology across our economy.”

SandboxAQ improves upon existing methods by delivering faster time-to-solution, while retaining accuracy. Initial customer milestones show that these technologies can decrease the time and cost of developing new therapies, and de-risk drug portfolios before entering preclinical and clinical stages.

“Our AQ-powered solutions accelerate the drug discovery and development process, mitigating its slow, complex, and error-prone nature,” said Nadia Harhen, leader of the AQBioSim division. “By shortening the discovery funnel, de-risking portfolios, and uncovering winning formulas earlier, we empower bio-pharma companies and research institutions to prioritize promising compounds, accelerate therapy development, extend patent lifetimes, drive revenue growth, and get cures to patients faster.”

The technologies were leveraged through a collaboration with UCSF’s Institute for Neurodegenerative Diseases in an effort to apply AI-powered simulation to rapidly identify potential therapies for neurodegenerative disorders. As part of the development, the researchers used SandboxAQ’s proprietary Absolute Free Energy Perturbation (AQ-FEPTM) software to generate thousands of predictions of molecular interactions, leading to some exciting new compounds.

“Neurodegenerative diseases are enormously complex and defy standard drug design,” said Stanley B. Prusiner, MD, who leads the UCSF Institute for Neurodegenerative Diseases. “We need rational and structure-based design methods that can address the challenging diseases we face. Given the devastating nature of these diseases and the lack of effective therapies to treat them, techniques that accelerate new leads and reduce our discovery timelines are greatly needed.”

SandboxAQ’s unique AQ-FEP software brings cutting edge physics-based accuracy to the initial stages of the drug discovery pipeline. The company’s team of physicists, biologists, as well as computational and medicinal chemists have a track record of developing highly effective strategies to scale up quantum chemical simulations using massively parallel classical hardware, including large scale linear algebra with TPUs, large scale DFT results (SandboxAQ presently holds the record for the largest N^3 DFT simulation) and a Post-Hartree-Fock method called DMRG, scaled up to unprecedented size. These tools serve as the catalyst for a suite of drug discovery solutions that combine the accuracy of quantum mechanical equations with the speed and power of AI, available on classical computing hardware. Subsequent advancements include large-scale molecular dynamics simulations able to handle complex, undruggable targets.

Other prominent researchers have praised SandboxAQ’s approach and ability to accelerate drug discovery. Dr. Siddhartha Mukherjee, staff cancer physician at Columbia University Medical Center and Pulitzer prize winner, said, “SandboxAQ is unique, and the only partner that I’ve seen deliver on first-in-class molecules. Their ability to do meaningful quantum chemistry computation on today’s hardware is critical to the first principles approach that is needed now, both in oncology and other major conditions.”

“We are excited about our partnership with SandboxAQ where we are accelerating drug candidate identification and optimization on novel targets within the Riboscience portfolio,” said Dr. Klaus Klumpp, co-founder and president of Riboscience. “SandboxAQ’s unprecedented large-scale absolute free energy perturbation solution is transforming our virtual screening campaign execution and allowing us to profile in-silico more than 20,000 ligands per day.”

“SandboxAQ’s AI-powered quantum technologies continue to revolutionize and disrupt industries, but few will experience such a transformative impact as bio-pharma and life sciences,” said Dr. Kristin Gilkes, EY Global Quantum Leader. “The company unabashedly seeks out the toughest challenges and applies technology and expertise to deliver impactful solutions – in this case, significantly advancing R&D for undruggable illnesses like cancer and Alzheimer’s that have confounded the industry for decades. EY is excited to be collaborating with SandboxAQ in its mission to reimagine drug discovery and development.”

For general information about SandboxAQ’s Quantum Simulation & Optimization offerings, please visit https://www.sandboxaq.com/simulation. Bio-pharma research organizations seeking information on how AQ-FEP can accelerate their current computational workflows, please email simulation@sandboxaq.com.

About SandboxAQ

SandboxAQ is an enterprise SaaS company, providing solutions at the nexus of AI and Quantum technology (AQ) to address some of the world’s greatest challenges. The company’s core team and inspiration formed at Alphabet Inc., emerging as an independent, growth-capital-backed company in 2022. SandboxAQ is backed by T. Rowe Price, Guggenheim Partners, Eric Schmidt (chairman of SandboxAQ), Breyer Capital, Marc Benioff and other leading investors. For more information, visit http://www.sandboxaq.com.

Share article on social media or email:

Labor Lawyers, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, File Lawsuit Against Prolink Healthcare, LLC, in PAGA-Only Action, Alleging California Labor Code Violations


Law Office of Blumenthal Nordrehaug Bhowmik De Blouw LLP

For more information about the lawsuit against Prolink Healthcare, LLC, call (800) 568-8020 to speak to an experienced California employment attorney today.

The San Francisco employment law attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, filed a lawsuit against Prolink Healthcare, LLC alleging the company violated Labor Code § 2699, et seq. seeking penalties for DEFENDANT’s alleged violation of California Labor Code §§ 201-203, 204 et seq., 210, 218, 221, 226(a), 226.7, 227.3, 246 et seq., 510, 512, 558(a)(1)(2), 1194, 1197, 1197.1, 1198, and 2802. The lawsuit against Prolink Healthcare, LLC is currently pending in the San Francisco County Superior Court, Case No. CGC-23-606525. To read a copy of the Complaint, please click here.

Additionally, Prolink Healthcare, LLC allegedly failed to reimburse employees for required business expenses. California Labor Code § 2802 expressly states that “an employer shall indemnify his or her employee for all necessary expenditures or losses incurred by the employee in direct consequence of the discharge of his or her duties…” During employment, Plaintiff and the AGGRIEVED EMPLOYEES were allegedly required to use their personal cellular phones as a result of and in furtherance of their job duties.

PAGA is a mechanism by which the State of California itself can enforce state labor laws through the employee suing under the PAGA who do so as the proxy or agent of the state’s labor law enforcement agencies. An action to recover civil penalties under PAGA is fundamentally a law enforcement action designed to protect the public and not to benefit private parties. The purpose of PAGA is not to recover damages or restitution, but to create a means of “deputizing” citizens as private attorneys general to enforce the Labor Code.

For more information about the lawsuit against Prolink Healthcare, LLC, call (800) 568-8020 to speak to an experienced California employment attorney today.

Blumenthal Nordrehaug Bhowmik De Blouw LLP is a labor law firm with law offices located in San Diego County, Riverside County, Los Angeles County, Sacramento County, Santa Clara County, Orange County, and San Francisco County. The firm has a statewide practice of representing employees on a contingency basis for violations involving unpaid wages, overtime pay, discrimination, harassment, wrongful termination, and other types of illegal workplace conduct.

***THIS IS AN ATTORNEY ADVERTISEMENT***

Share article on social media or email:

Statement from Catholics for Choice President Jamie L. Manson on the One-Year Anniversary of the Supreme Court’s Overturning of Roe v. Wade


Catholics for Choice recommits to being louder than ever about our faithfully-formed beliefs in conscience, in social justice, and in religious freedom… We will continue to fight until the fundamental right to abortion is once again the law of the land.

Catholics for Choice, which uplifts and amplifies the voices of the majority of Catholics who believe in reproductive freedom, released the following statement from President Jamie L. Manson, M.Div., marking the one-year anniversary of the June 24, 2022 Supreme Court decision in Dobbs v. Jackson Women’s Health Organization that overturned Roe v. Wade:

“One year ago, the majority-Catholic Supreme Court overturned Roe v. Wade and completed the decades-long religious crusade, spearheaded by the U.S. Catholic bishops, to take away our most fundamental freedom: our ability to control our own fertility and determine our own destiny.

“Here’s a crucial, overlooked fact about the Dobbs decision: All of the five justices that overturned Roe v. Wade are, or were raised, Catholic. The anti-abortion opposition that successfully overturned Roe v. Wade is a Catholic one.

“When Catholics for Choice gathered in anger on the steps of the Supreme Court that day, we knew that the Dobbs decision would give right-wing leaders license to codify their fringe religious beliefs into civil law, with a devastating impact on millions of women and pregnant people across the country. And in the year that followed, those fears have been realized: a recent study from ANSIRH found that in states where there are abortion bans and restrictions, the morbidity of pregnant patients has doubled. Long-term side effects from the delay and poor quality of care include infertility, heart attack, stroke, uncontrolled hypertension, and chronic pelvic pain and infection.

“It cannot be overstated that anti-choice Catholic forces are responsible for this suffering. At Catholics for Choice, we know that our opposition is a religious force, falsely using Catholic and Christian identities to infringe upon the rights and consciences of thousands across the country.

“The year since Dobbs has shown us just how out of step those anti-choice forces are with U.S. Catholics, the majority of whom support abortion in all or most cases. We’ve turned out in droves, in red states and blue, to defend abortion rights at the ballot box. We’ve lobbied elected officials, testified at legislative hearings, spoken up in the media, and organized. We’re more committed than ever to the urgent, lifesaving work of restoring, protecting, and expanding abortion access.

“As we acknowledge the one-year anniversary of this decision, Catholics for Choice recommits to being louder than ever about our faithfully-formed beliefs in conscience, in social justice, and in religious freedom. And we are calling on the hundreds of thousands of Catholics who agree – and who can overshadow the radical, anti-choice Catholic minority – to join us and declare, ‘I am a Catholic for Choice!’ We will continue to fight until the fundamental right to abortion is once again the law of the land.”

For the month of June, Catholics for Choice launched the “I am a Catholic for Choice” campaign, which includes a pledge for pro-choice Catholics to be silent no more; a solidarity pledge for allies who are affected by the religious overreach of the Catholic hierarchy; and “A Pro-Choice Catholic Was Here” postcards that people can post on social media and leave in church pews, on bulletin boards, in coffee shops, and more. Catholics for Choice is also hosting “How I Became a Catholic for Choice: A Conversation with Jamie Manson” on June 28. More details about these activities can be found at http://www.catholicsforchoice.org/iamacatholicforchoice.

Catholics for Choice shapes and advances sexual and reproductive ethics that are based on justice, reflect a commitment to a person’s well-being and respect, and affirm the capacity of all people to make moral decisions about their lives.

Contact: John Becker, Press Secretary

Phone: 202-203-0931

Email: jbecker@catholicsforchoice.org

Share article on social media or email: